TY - JOUR
T1 - Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
AU - De Stefano, Valerio
AU - Za, Tommaso
AU - Rossi, Elena
AU - Vannucchi, Alessandro M.
AU - Ruggeri, Marco
AU - Elli, Elena
AU - Micò, Caterina
AU - Tieghi, Alessia
AU - Cacciola, Rossella R.
AU - Santoro, Cristina
AU - Vianelli, Nicola
AU - Guglielmelli, Paola
AU - Pieri, Lisa
AU - Scognamiglio, Francesca
AU - Cacciola, Emma
AU - Rodeghiero, Francesco
AU - Pogliani, Enrico M.
AU - Finazzi, Guido
AU - Gugliotta, Luigi
AU - Leone, Giuseppe
AU - Barbui, Tiziano
PY - 2010/2
Y1 - 2010/2
N2 - Evidence suggests that the JAK2 V617F mutation is associated with an increased risk of first thrombosis in patients with essential thrombocythemia (ET). Whether this mutation is also a risk factor for recurrent thrombosis is currently unknown. To investigate the impact of the JAK2 V617F mutation on the risk of recurrent thrombosis in patients with ET, we carried out a multicentre retrospective cohort study. We recruited 143 patients with previous arterial (64.4%) or venous major thrombosis (34.8%) or both (0.8%); 98 of them (68.5%) carried the mutation. Thrombosis recurred in 43 of the patients (30%); overall, after adjustment for sex, age, presence of vascular risk factors, and treatment after the first thrombosis, the presence of the JAK2 mutation did not predict recurrence (multivariable hazard ratio, HR, 0.88, 95% CI 0.46-1.68). Indeed, the individuals homozygous for the JAK2 V617F (allele burden >50%) mutation had an increased risk of recurrence in comparison with wild-type patients (HR 6.15, 95% CI 1.51-24.92). In conclusion, a homozygous JAK2 V617F mutation is an independent risk factor for recurrent thrombosis in patients with ET.
AB - Evidence suggests that the JAK2 V617F mutation is associated with an increased risk of first thrombosis in patients with essential thrombocythemia (ET). Whether this mutation is also a risk factor for recurrent thrombosis is currently unknown. To investigate the impact of the JAK2 V617F mutation on the risk of recurrent thrombosis in patients with ET, we carried out a multicentre retrospective cohort study. We recruited 143 patients with previous arterial (64.4%) or venous major thrombosis (34.8%) or both (0.8%); 98 of them (68.5%) carried the mutation. Thrombosis recurred in 43 of the patients (30%); overall, after adjustment for sex, age, presence of vascular risk factors, and treatment after the first thrombosis, the presence of the JAK2 mutation did not predict recurrence (multivariable hazard ratio, HR, 0.88, 95% CI 0.46-1.68). Indeed, the individuals homozygous for the JAK2 V617F (allele burden >50%) mutation had an increased risk of recurrence in comparison with wild-type patients (HR 6.15, 95% CI 1.51-24.92). In conclusion, a homozygous JAK2 V617F mutation is an independent risk factor for recurrent thrombosis in patients with ET.
KW - Essential thrombocythemia
KW - JAK2 V617F mutation
KW - Recurrent thrombosis
UR - http://www.scopus.com/inward/record.url?scp=74049141807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049141807&partnerID=8YFLogxK
U2 - 10.1007/s00277-009-0788-5
DO - 10.1007/s00277-009-0788-5
M3 - Article
C2 - 19582452
AN - SCOPUS:74049141807
SN - 0939-5555
VL - 89
SP - 141
EP - 146
JO - Revue d'hématologie
JF - Revue d'hématologie
IS - 2
ER -